|
INmune Bio Granted Phase I Clinical Trial Authorization of Lead Product INKmune™ in Refractory and Recurrent Ovarian Cancer Patients
|
18 Dec, 2018 |
|
Trastuzumab-Resistant HER2 Positive Breast Cancer Reversed By Treatment with INB03
|
11 Dec, 2018 |
|
INmune Bio Announces Publication of Myeloid-Derived Suppressor Cells (MDSC) Report in the Cell’s Trends in Pharmacological Sciences Journal
|
06 Dec, 2018 |
|
INmune Nominated for Buzz of Bio Award at 2019 CEO & Investor Conference -Voting begins today: Click here to cast your vote-
|
03 Dec, 2018 |
|
Data from University of Pittsburgh on INB03TM for Treatment of Melanoma Presented at the 33rd Annual Society for Immunotherapy of Cancer (SITC) Meeting
|
15 Nov, 2018 |
|
INmune Bio to Present at National Investment Banking Association Conference
|
30 Oct, 2018 |
|
INmune Bio Co-Founder and CSO Named Regional VP to the Board of International Society of Cell and Gene Therapy (ISCT)
|
17 Oct, 2018 |
|
INmune Bio Named Finalist for Lifestars’ U.S. Private Company of the Year Award
|
26 Sep, 2018 |
|
INmune Bio Co-Founder and Chief Scientific Officer Mark Lowdell, Ph.D., Chairing Sessions at International Society of Cell and Gene Therapy (ISCT) European Regional Meeting
|
12 Sep, 2018 |
|
INmune Bio to Present at Two Prestigious Cambridge Healthtech Institute Events
|
27 Aug, 2018 |
|
INmune Bio CEO Dr. Raymond J. Tesi to Present at 14th Annual Biomarkers & Immuno-Oncology World Congress
|
07 Jun, 2018 |
|
INmune Bio Initiates Phase I Clinical Trial of INB03
|
23 May, 2018 |
|
INmune Bio’s Professor Mark Lowdell to Participate as Expert Speaker at the Third Annual Innate Killer Summit 2018
|
26 Mar, 2018 |
|
INmune Bio Appoints Scott Juda to Board of Directors
|
13 Mar, 2018 |
|
INmune Bio to Present at Upcoming Conferences
|
27 Feb, 2018 |
|
INmune Bio presenting at NobleCon14 on January 29th
|
23 Jan, 2018 |
